DIACEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103 GBX | 0.00% |
|
-0.48% | +18.39% |
| Apr. 02 | Roadside shares suspended; Adnams looks for funds | AN |
| Mar. 21 | Diaceutics upgrades diagnositc commercialisation platform, DXRX | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 70.97 | 112.2 | 85.75 | 63.68 | 86.99 | 86.99 | - |
| Enterprise Value (EV) 1 | 59.25 | 87.1 | 66.08 | 43.84 | 70.86 | 73.5 | 72.14 |
| P/E ratio | 165 x | 393 x | - | 89.9 x | -61 x | -54.5 x | 69.9 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.3 x | 8.84 x | 6.15 x | 3.26 x | 3.64 x | 2.94 x | 2.31 x |
| EV / Revenue | 4.42 x | 6.86 x | 4.74 x | 2.25 x | 2.97 x | 2.48 x | 1.91 x |
| EV / EBITDA | 24.7 x | 162 x | 28.1 x | 12.2 x | 31.9 x | 26.6 x | 10.2 x |
| EV / FCF | - | - | -13.1 x | 194 x | -18.1 x | -24.2 x | 56.9 x |
| FCF Yield | - | - | -7.61% | 0.52% | -5.52% | -4.14% | 1.76% |
| Price to Book | - | - | - | 1.53 x | 2.11 x | 2.23 x | 2.15 x |
| Nbr of stocks (in thousands) | 69,583 | 84,069 | 84,069 | 84,339 | 84,452 | 84,452 | - |
| Reference price 2 | 1.020 | 1.335 | 1.020 | 0.7550 | 1.030 | 1.030 | 1.030 |
| Announcement Date | 3/16/20 | 3/15/21 | 3/22/22 | 4/17/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.4 | 12.7 | 13.94 | 19.5 | 23.89 | 29.61 | 37.73 |
| EBITDA 1 | 2.4 | 0.539 | 2.349 | 3.583 | 2.225 | 2.766 | 7.083 |
| EBIT 1 | 0.7404 | -0.658 | 0.55 | 0.574 | -2.085 | -2.331 | 1.061 |
| Operating Margin | 5.53% | -5.18% | 3.94% | 2.94% | -8.73% | -7.87% | 2.81% |
| Earnings before Tax (EBT) 1 | 0.4973 | -0.682 | - | 0.564 | -1.889 | -2.17 | 1.55 |
| Net income 1 | 0.3979 | 0.263 | 0.561 | 0.724 | -1.667 | -2.004 | 0.62 |
| Net margin | 2.97% | 2.07% | 4.02% | 3.71% | -6.98% | -6.77% | 1.64% |
| EPS 2 | 0.006200 | 0.003400 | - | 0.008400 | -0.0169 | -0.0189 | 0.0147 |
| Free Cash Flow 1 | - | - | -5.031 | 0.226 | -3.915 | -3.041 | 1.267 |
| FCF margin | - | - | -36.08% | 1.16% | -16.39% | -10.27% | 3.36% |
| FCF Conversion (EBITDA) | - | - | - | 6.31% | - | - | 17.88% |
| FCF Conversion (Net income) | - | - | - | 31.22% | - | - | 204.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/15/21 | 3/22/22 | 4/17/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 11.98 | 9.924 | 14.02 | 12.55 | 16.37 |
| EBITDA 1 | - | - | 3.31 | -0.232 | 2.497 | 0.16 | 2.61 |
| EBIT 1 | - | - | 1.637 | -2.166 | 0.255 | -1.87 | 0.64 |
| Operating Margin | - | - | 13.67% | -21.83% | 1.82% | -14.9% | 3.91% |
| Earnings before Tax (EBT) 1 | - | - | 1.695 | -1.955 | - | - | - |
| Net income 1 | -0.335 | -0.767 | 1.491 | -1.485 | 0.205 | -1.77 | 0.55 |
| Net margin | - | - | 12.45% | -14.96% | 1.46% | -14.1% | 3.36% |
| EPS 2 | -0.004000 | -0.009100 | 0.0173 | -0.0176 | 0.002150 | -0.0205 | 0.006400 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 9/14/21 | 9/27/22 | 4/17/23 | 9/26/23 | - | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 11.7 | 25.1 | 19.7 | 19.8 | 16.1 | 13.5 | 14.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -5.03 | 0.23 | -3.91 | -3.04 | 1.27 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 0.4900 | 0.4900 | 0.4600 | 0.4800 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 2.93 | 6.29 | 5.6 | 4.87 | 6.13 | 5.6 | 5.6 |
| Capex / Sales | 21.84% | 49.57% | 40.17% | 24.97% | 25.68% | 18.91% | 14.84% |
| Announcement Date | 3/16/20 | 3/15/21 | 3/22/22 | 4/17/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.03
GBP
Average target price
1.666
GBP
Spread / Average Target
+61.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.39% | 109M | |
| +5.73% | 4.05B | |
| +23.11% | 1.94B | |
| -36.44% | 1.97B | |
| -1.59% | 1.74B | |
| -15.36% | 1.61B | |
| -24.30% | 1.36B | |
| -5.20% | 1.2B | |
| -6.85% | 1.02B | |
| +119.33% | 694M |
- Stock Market
- Equities
- DXRX Stock
- Financials Diaceutics PLC
